Learn

This is a summary of the Australian & New Zealand Urogenital & Prostate Cancer Trials Group ASM 2025 Conference Review which was recently held in Sydney.

Commentary provided by Associate Professor Andrew Weickhardt.

Details

In this edition we feature:

-  Impacts of AR genomic structural rearrangements in prostate cancer
-  COMBAT: tissue biomarkers in MIBC undergoing curative treatment
-  ANZUP 1301: intravesical BCG ± mitomycin C in high-risk, BCG-naïve NMIBC
-  Biomarkers & precision strategies in hormone-sensitive metastatic prostate cancer
-  TheraP: biomarker analysis of Lu-PSMA response in mCRPC
-  Mitochondrial dysfunction & valine metabolism in CRPC
-  DKI vs. VI-RADS for pre-TURBT bladder cancer staging
-  Role of physical examination for relapse monitoring in stage 1 testicular germ cell tumours
-  ProFocal: a new laser focal ablation tool for apical prostate cancer

To access this publication please click ‘Enrol Now’ and you’ll be directed to  the publication. Then sign up to Research Review at no cost. You can then login with your email and password. If you require any assistance please email Research Review – trish@researchreview.com.au

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.